Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes
Abstract
1. Introduction
2. Prevalence and Risk Factors
3. MASLD and Insulin Resistance in T1D
4. MASLD and Diabetes Complications in T1D
Author (Year) | Design | Sample Size (n) | MASLD Diagnosis | Complications | Inclusion/Exclusion | Key Findings |
---|---|---|---|---|---|---|
Mantovani et al., 2024 [31] | Retrospective, multi-center, cross-sectional | 1409 | Non-invasive biomarkers; hepatic steatosis index (HSI > 36) and FIB-4 index (≥1.3 for significant fibrosis) | Chronic Kidney Disease (CKD); diabetic retinopathy | Inclusion: Adults with T1D; Exclusion: Not specified | MASLD with fibrosis was associated with higher risk of CKD (aOR 1.76; 95% CI 1.05–2.96); MASLD without fibrosis was associated with higher risk of diabetic retinopathy (aOR 1.49; 95% CI 1.13–1.46); The findings suggest that MASLD is independently associated with microvascular complications in T1D. |
Fuhri Snethlage et al., 2024 [32] | Cross-sectional, observational | 453 | Vibrationcontrolled transient elastography (VCTE); MASLD defined by CAP score ≥ 280 dB/m and fibrosis by LSM ≥ 8.0 kPa | Cardiovascular disease (CVD); microvascular complications; high blood pressure | Inclusion: Adults with T1D; Exclusion: Not specified | Prevalence of steatosis: 9.5%, fibrosis: 3.5%. Fibrosis was associated with older age, longer diabetes duration, higher BMI, and systolic BP. Machine learning identified duration of diabetes, age, and systolic BP as top predictors. |
Maffeis et al., 2024 [33] | Cross-sectional, observational | 244 | Hepatic steatosis defined by ultrasound, plus ≥ 1 cardiometabolic risk factor (per MASLD definition) | Cardiovascular disease (CVD) | Inclusion: Children and adolescents with T1D; Exclusion: Not specified | MASLD prevalence was 27.5%. Higher HbA1c (from onset), time above range (TAR), and LDL cholesterol were independently associated with MASLD. The findings suggest that poor glycemic control and dyslipidemia contribute to MASLD risk in pediatric T1D patients. |
Targher et al., 2010 [9] | Cross-sectional | 250 | History + liver ultrasound | Cardiovascular disease (coronary, cerebrovascular, and peripheral) | Inclusion: T1D patients with liver ultrasound data, attending diabetes clinic regularly; Exclusion: Not specified | MASLD prevalence was 44.4%. MASLD was independently associated with higher prevalence of coronary (10.8% vs. 1.1%), cerebrovascular (37.3% vs. 5.5%), and peripheral (24.5% vs. 2.5%) vascular disease. Adjusted OR for CVD = 7.36. |
Targher et al., 2010 [34] | Cross-sectional, biopsy-based, case-control | 160 (80 NASH + 80 controls) | Liver biopsy (NASH); the control group had no steatosis | Chronic Kidney Disease (CKD); low eGFR; albuminuria | Inclusion: Overweight adults matched by age, sex, BMI; 80 with biopsy-proven NASH, 80 controls without steatosis; Exclusion: Not specified | NASH patients had lower eGFR (75.3 vs. 87.5), more albuminuria (14% vs. 2.5%), and higher CKD prevalence (25% vs. 3.7%). Differences remained significant after adjusting for insulin resistance, metabolic syndrome, and other factors. Severity of NASH (fibrosis) correlated with worse kidney function. |
Mantovani et al., 2017 [35] | Retrospective, cross-sectional | 286 | Ultrasonography | Distal symmetric polyneuropathy | Inclusion: White adults with T1D attending foot screening; Exclusion: Excess alcohol intake and other known liver diseases | MASLD was present in 52.4% of participants. MASLD was associated with significantly higher prevalence of polyneuropathy (51.0% vs. 17.1%). Adjusted OR for polyneuropathy = 2.23, independent of glycemic control, CKD, and metabolic risk factors. |
Serra-Planas et al., 2017 [36] | Cross-sectional | 100 | Abdominal ultrasonography | Subclinical CVD (↑ CIMT, CACS > 0, carotid plaques) | Inclusion: Adults with T1D undergoing abdominal + carotid ultrasound and cardiac CT; Exclusion: Not specified | MASLD prevalence was 12%. T1D subjects with MASLD had higher CIMT (0.65 ± 0.17 vs. 0.55 ± 0.14 mm; p = 0.029) but no significant differences in CACS or plaque presence. Elevated liver enzymes (>20 U/L) were also linked to worse imaging markers. |
Zhang et al., 2023 [37] | Cross-sectional | 12,990 | Ultrasound | Carotid plaque | Inclusion: Chinese aged adults; Exclusion: Excess alcohol intake (men > 210 g/week, women > 140 g/week); censored for elevated ALT (≥75 IU/L), CVD, and obesity in sensitivity analyses. | MASLD was associated with higher carotid plaque prevalence (22.4% vs. 16.3%). Adjusted OR = 1.89 (95% CI: 1.59–2.24). Association remained significant after adjusting for multiple metabolic and clinical variables and after sensitivity analyses. |
5. Conclusions
6. Future Directions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Memaj, P.; Jornayvaz, F.R. Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes: Prevalence and Pathophysiology. Front. Endocrinol. 2022, 13, 1031633. [Google Scholar] [CrossRef]
- Yki-Järvinen, H. Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD). Diabetologia 2016, 59, 1104–1111. [Google Scholar] [CrossRef] [PubMed]
- Rinella, M.E. Nonalcoholic Fatty Liver Disease: A Systematic Review. JAMA 2015, 313, 2263. [Google Scholar] [CrossRef] [PubMed]
- Haas, J.T.; Francque, S.; Staels, B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu. Rev. Physiol. 2016, 78, 181–205. [Google Scholar] [CrossRef]
- Syed, F.Z. Type 1 Diabetes Mellitus. Ann. Intern. Med. 2022, 175, ITC33–ITC48. [Google Scholar] [CrossRef]
- Scheen, A.J. Pathophysiology of Type 2 Diabetes. Acta Clin. Belg. 2003, 58, 335–341. [Google Scholar] [CrossRef]
- Chiang, J.L.; Kirkman, M.S.; Laffel, L.M.B.; Peters, A.L.; on behalf of the Type 1 Diabetes Sourcebook Authors. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. Diabetes Care 2014, 37, 2034–2054. [Google Scholar] [CrossRef]
- de Vries, M.; Westerink, J.; Kaasjager, K.H.A.H.; de Valk, H.W. Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J. Clin. Endocrinol. Metab. 2020, 105, 3842–3853. [Google Scholar] [CrossRef] [PubMed]
- Targher, G.; Bertolini, L.; Padovani, R.; Rodella, S.; Zoppini, G.; Pichiri, I.; Sorgato, C.; Zenari, L.; Bonora, E. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Association with Cardiovascular Disease in Patients with Type 1 Diabetes. J. Hepatol. 2010, 53, 713–718. [Google Scholar] [CrossRef]
- Targher, G.; Mantovani, A.; Pichiri, I.; Mingolla, L.; Cavalieri, V.; Mantovani, W.; Pancheri, S.; Trombetta, M.; Zoppini, G.; Chonchol, M.; et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with an Increased Incidence of Chronic Kidney Disease in Patients with Type 1 Diabetes. Diabetes Care 2014, 37, 1729–1736. [Google Scholar] [CrossRef]
- Cao, L.; An, Y.; Liu, H.; Jiang, J.; Liu, W.; Zhou, Y.; Shi, M.; Dai, W.; Lv, Y.; Zhao, Y.; et al. Global Epidemiology of Type 2 Diabetes in Patients with NAFLD or MAFLD: A Systematic Review and Meta-Analysis. BMC Med. 2024, 22, 101. [Google Scholar] [CrossRef]
- Chen, L.-W.; Huang, P.-R.; Chien, C.-H.; Lin, C.-L.; Chien, R.-N. A Community-Based Study on the Application of Fatty Liver Index in Screening Subjects with Nonalcoholic Fatty Liver Disease. J. Formos. Med. Assoc. 2020, 119, 173–181. [Google Scholar] [CrossRef]
- Boncan, D.A.T.; Yu, Y.; Zhang, M.; Lian, J.; Vardhanabhuti, V. Machine Learning Prediction of Hepatic Steatosis Using Body Composition Parameters: A UK Biobank Study. npj Aging 2024, 10, 4. [Google Scholar] [CrossRef]
- Singh, J.; Ibrahim, B.; Jackson, N.J.; Khalil, H.; Valenzuela, J.; Yanny, B.; Saab, S. Lower FIB-4 Threshold in Patients with Diabetes Improves Diagnostic Accuracy of the Test in a Hispanic Population. Transl. Gastroenterol. Hepatol. 2024, 9, 16. [Google Scholar] [CrossRef]
- Mosca, A.; Della Volpe, L.; Alisi, A.; Veraldi, S.; Francalanci, P.; Maggiore, G. Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents with Non-Alcoholic Fatty Liver Disease. Front. Pediatr. 2022, 10, 885576. [Google Scholar] [CrossRef]
- Mertens, J.; Weyler, J.; Dirinck, E.; Vonghia, L.; Kwanten, W.J.; Mortelmans, L.; Peleman, C.; Chotkoe, S.; Spinhoven, M.; Vanhevel, F.; et al. Prevalence, Risk Factors and Diagnostic Accuracy of Non-Invasive Tests for NAFLD in People with Type 1 Diabetes. JHEP Rep. 2023, 5, 100753. [Google Scholar] [CrossRef] [PubMed]
- Davidson, M.B. Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes. Diabetes Care 2003, 26, 3179. [Google Scholar] [CrossRef] [PubMed]
- Dorairaj, V.; Sulaiman, S.A.; Abu, N.; Abdul Murad, N.A. Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. Biomedicines 2021, 10, 15. [Google Scholar] [CrossRef]
- Lipman, T.H.; Hayman, L.L.; Fabian, C.E. Risk factors for cardiovascular disease in children with type I diabetes: Part II. J. Pediatr. Nurs. 1997, 12, 318–322. [Google Scholar] [CrossRef] [PubMed]
- de Vries, M.; Westerink, J.; El-Morabit, F.; Kaasjager, H.A.H.; de Valk, H.W. Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Association with Surrogate Markers of Insulin Resistance in Patients with Type 1 Diabetes. Diabetes Res. Clin. Pract. 2022, 186, 109827. [Google Scholar] [CrossRef] [PubMed]
- Grzelka-Woźniak, A.; Uruska, A.; Szymańska-Garbacz, E.; Araszkiewicz, A.; Jabłkowski, M.; Czupryniak, L.; Zozulińska-Ziółkiewicz, D. Indirect Insulin Resistance Markers Are Associated with Nonalcoholic Fatty Liver Disease in Type 1 Diabetes. Pol. Arch. Intern. Med. 2023, 133, 16404. [Google Scholar] [CrossRef]
- de Vries, M.; Westerink, J.; Kaasjager, H.a.H.; de Valk, H.W.; UCC-SMART Study Group. Association of Physical Activity and Sports Participation with Insulin Resistance and Non-Alcoholic Fatty Liver Disease in People with Type 1 Diabetes. Diabet. Med. 2024, 41, e15317. [Google Scholar] [CrossRef]
- Perseghin, G.; Lattuada, G.; De Cobelli, F.; Esposito, A.; Costantino, F.; Canu, T.; Scifo, P.; De Taddeo, F.; Maffi, P.; Secchi, A.; et al. Reduced Intrahepatic Fat Content Is Associated with Increased Whole-Body Lipid Oxidation in Patients with Type 1 Diabetes. Diabetologia 2005, 48, 2615–2621. [Google Scholar] [CrossRef]
- Sviklāne, L.; Olmane, E.; Dzērve, Z. Fatty Liver Index and Hepatic Steatosis Index for Prediction of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes. J. Gastroenterol. Hepatol. 2017, 33, 270–276. [Google Scholar] [CrossRef]
- Gregory, J.M.; Cherrington, A.D.; Moore, D.J. The Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes. Diabetes 2020, 69, 837–847. [Google Scholar] [CrossRef]
- Schauer, I.E.; Snell-Bergeon, J.K.; Bergman, B.C.; Maahs, D.M.; Kretowski, A.; Eckel, R.H.; Rewers, M. Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects with and Without Type 1 Diabetes: The CACTI Study. Diabetes 2010, 60, 306–314. [Google Scholar] [CrossRef] [PubMed]
- Mieli-Vergani, G.; Vergani, D.; Czaja, A.J.; Manns, M.P.; Krawitt, E.L.; Vierling, J.M.; Lohse, A.W.; Montano-Loza, A.J. Autoimmune Hepatitis. Nat. Rev. Dis. Primers 2018, 4, 18017. [Google Scholar] [CrossRef] [PubMed]
- Mertens, J.; Van Gaal, L.F.; Francque, S.M.; De Block, C. NAFLD in Type 1 Diabetes: Overrated or Underappreciated? Ther. Adv. Endocrinol. 2021, 12, 20420188211055557. [Google Scholar] [CrossRef] [PubMed]
- Perseghin, G.; Lattuada, G.; Danna, M.; Sereni, L.P.; Maffi, P.; De Cobelli, F.; Battezzati, A.; Secchi, A.; Del Maschio, A.; Luzi, L. Insulin Resistance, Intramyocellular Lipid Content, and Plasma Adiponectin in Patients with Type 1 Diabetes. Am. J. Physiol. Endocrinol. Metab. 2003, 285, E1174–E1181. [Google Scholar] [CrossRef]
- De Vries, M.; Kaasjager, K.H.A.H.; De Valk, H.W. Comment on Parente et al. The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults with Type 1 Diabetes. Diabetes Care 2021, 44, 1706–1713. Diabetes Care 2022, 45, e7. [Google Scholar] [CrossRef]
- Mantovani, A.; Morieri, M.L.; Aldigeri, R.; Palmisano, L.; Masulli, M.; Bonomo, K.; Baroni, M.G.; Cossu, E.; Cimini, F.A.; Cavallo, G.; et al. MASLD, Hepatic Steatosis and Fibrosis Are Associated with the Prevalence of Chronic Kidney Disease and Retinopathy in Adults with Type 1 Diabetes Mellitus. Diabetes Metab. 2024, 50, 101497. [Google Scholar] [CrossRef] [PubMed]
- Fuhri Snethlage, C.M.; Meijnikman, A.S.; Mak, A.L.; Rampanelli, E.; Voermans, B.; Callender, C.A.K.; de Groen, P.; Roep, B.O.; van Raalte, D.H.; Knop, F.K.; et al. Prevalence and Predictive Features of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 1 Diabetes. Eur. J. Endocrinol. 2024, 190, 391–400. [Google Scholar] [CrossRef] [PubMed]
- Maffeis, C.; Piona, C.; Morandi, A.; Marigliano, M.; Morotti, E.; Mancioppi, V.; Caiazza, E.; Zusi, C.; Emiliani, F.; Mantovani, A.; et al. Glycaemic Control Metrics and Metabolic Dysfunction-Associated Steatotic Liver Disease in Children and Adolescents with Type 1 Diabetes. Diabetes Obes. Metab. 2024, 26, 5896–5905. [Google Scholar] [CrossRef]
- Targher, G.; Bertolini, L.; Rodella, S.; Lippi, G.; Zoppini, G.; Chonchol, M. Relationship between Kidney Function and Liver Histology in Subjects with Nonalcoholic Steatohepatitis. Clin. J. Am. Soc. Nephrol. 2010, 5, 2166–2171. [Google Scholar] [CrossRef]
- Mantovani, A.; Rigolon, R.; Mingolla, L.; Pichiri, I.; Cavalieri, V.; Salvotelli, L.; Stoico, V.; Zoppini, G.; Bonora, E.; Targher, G. Nonalcoholic Fatty Liver Disease Is Associated with an Increased Prevalence of Distal Symmetric Polyneuropathy in Adult Patients with Type 1 Diabetes. J. Diabetes Its Complicat. 2017, 31, 1021–1026. [Google Scholar] [CrossRef]
- Serra-Planas, E.; Aguilera, E.; Castro, L.; Rodríguez, R.; Salinas, I.; Lucas, A.; Joaquín, C.; Puig, R.; Mauricio, D.; Puig-Domingo, M. Low Prevalence of Non-Alcoholic Fatty Liver Disease in Patients with Type 1 Diabetes Is Associated with Decreased Subclinical Cardiovascular Disease. J. Diabetes 2017, 9, 1065–1072. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Zheng, M.; Lei, H.; Jiang, Z.; Chen, Y.; He, H.; Zhao, G.; Huang, H. A Clinical Study of the Correlation between Metabolic-Associated Fatty Liver Disease and Coronary Plaque Pattern. Sci. Rep. 2023, 13, 7224. [Google Scholar] [CrossRef]
Author (Year) | Design | Sample Size (n) | MASLD Diagnosis | Markers for Insulin Resistance | Inclusion/Exclusion | Key Findings |
---|---|---|---|---|---|---|
Grezelka-Woźniak et al., 2023 [21] | Cross-sectional, observational | 151 | Transient elastography (TE); MASLD defined as controlled attenuation parameter (CAP) ≥238 dB/m | Estimated Glucose Disposal Rate (eGDR); Visceral Adiposity Index (VAI); Triglyceride-to-HDL- Cholesterol Ratio (TG/HDL-C) | Inclusion: Adults with T1D; Exclusion: Not specified | MASLD was present in 43% of patients; indirect insulin resistance markers were independently associated with MASLD |
de Vries et al., 2024 [22] | Cross-sectional, observational | 254 (150 with TE) | Transient elastography (TE); MASLD defined via imaging-based assessment | Estimated Glucose Disposal Rate (eGDR) | Inclusion: Adults with T1D from secondary/tertiary care centers. Exclusion: Not specified | No dose-dependent association found between physical activity and insulin resistance/MASLD. Sports participation was significantly associated with higher insulin sensitivity (eGDR) and lower odds of MASLD (OR 0.21; 95% CI 0.08–0.56). |
de Vries et al., 2022 [20] | Prospective, observational | 150 | Transient elastography (TE); MASLD defined as hepatic steatosis (HS) with or without fibrosis/cirrhosis | Estimated Glucose Disposal Rate (eGDR); metabolic syndrome | Inclusion: Adults with T1D; Exclusion: Known secondary causes of liver disease | MASLD was present in 20% of patients; 3.3% had fibrosis; lower eGDR (OR 0.62; 95% CI 0.49–0.77) and presence of metabolic syndrome (OR 7.62; 95% CI 2.95–19.77) were significantly associated with MASLD, suggesting that insulin resistance is a key risk factor |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vermillion, B.; Mao, Y. Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes. J. Clin. Med. 2025, 14, 5502. https://doi.org/10.3390/jcm14155502
Vermillion B, Mao Y. Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes. Journal of Clinical Medicine. 2025; 14(15):5502. https://doi.org/10.3390/jcm14155502
Chicago/Turabian StyleVermillion, Brynlee, and Yuanjie Mao. 2025. "Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes" Journal of Clinical Medicine 14, no. 15: 5502. https://doi.org/10.3390/jcm14155502
APA StyleVermillion, B., & Mao, Y. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes. Journal of Clinical Medicine, 14(15), 5502. https://doi.org/10.3390/jcm14155502